PLUR Pluri Inc.
USHealthcareAs of 2026-07-10 16:00
Why PLUR matters now
Pluri Inc. (PLUR) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.72 with -3.65% on the session and $15.4M in market capitalization; recent performance reads 1-month -19.84% and YTD -32.44%.
The latest financial table shown here is Q3 2026, with revenue of $167.0K, net income of $-6.2M, and EPS of $-0.55. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -119.4%.
The latest indexable market news headline is "Plurilock Announces Results of Annual General Meeting" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Manieu Alexandre Weinstein filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.09
P/S
16.83
EV/EBITDA
-1.85
DCF Value
$-20.93
FCF Yield
-119.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.0%
Operating Margin
-2412.1%
Net Margin
-2424.7%
ROE
203.6%
ROA
-100.4%
ROIC
-117.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $167.0K | $-6.2M | $-0.55 |
| Q2 2026 | $198.0K | $-6.5M | $-0.71 |
| Q1 2026 | $316.0K | $-5.8M | $-0.65 |
| Q4 2025 | $398.0K | $-7.6M | $-0.96 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
0.63
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.